• 1
    Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 14151428.
  • 2
    Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433438.
  • 3
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356359.
  • 4
    Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004; 10: 886897.
  • 5
    Reich D, Rothstein K, Manzarbeitia C, Munoz S. Common medical diseases after liver transplantation. Semin Gastrointest Dis 1998; 9: 110125.
  • 6
    Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 1995; 60: 10571060.
  • 7
    Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13: 11091114.
  • 8
    Hanouneh IA, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14: 12871293.
  • 9
    Francioso S, Angelico F, Baiocchi L, Tisone G, Lenci I, Carbone M, et al. High prevalence of metabolic syndrome and long-term survival after liver transplantation. J Hepatol 2008; 48: S82.
  • 10
    Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008; 14: 16481654.
  • 11
    Munoz SJ, Elgenaidi H. Cardiovascular risk factors after liver transplantation. Liver Transpl 2005; 11: S52S56.
  • 12
    Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 2001; 7: S13S21.
  • 13
    Jindal RM, Sidner RA, Hughes D, Pescovitz MD, Leapman SB, Milgrom ML, et al. Metabolic problems in recipients of liver transplants. Clin Transplant 1996; 10: 213217.
  • 14
    Navasa M, Bustamante J, Marroni C, Gonzalez E, Andreu H, Esmatjes E, et al. Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol 1996; 25: 6471.
  • 15
    Sutedja DS, Wai CT, Teoh KF, Lee YM, Diddapur RK, Isaac J, et al. Long-term post-liver transplant complications of renal impairment and diabetes mellitus: data from Singapore. Singapore Med J 2006; 47: 604608.
  • 16
    Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 2000; 69: 781789.
  • 17
    Guckelberger O, Bechstein WO, Neuhaus R, Luesebrink R, Lemmens HP, Kratschmer B, et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant 1997; 11: 6065.
  • 18
    Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000; 32: 8790.
  • 19
    Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 10661072.
  • 20
    Tueche SG. Diabetes mellitus after liver transplant: new etiologic clues and cornerstones for understanding. Transplant Proc 2003; 35: 14661468.
  • 21
    John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002; 8: 708713.
  • 22
    Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73: 901906.
  • 23
    Munoz SJ, Deems RO, Moritz MJ, Martin P, Jarrell BE, Maddrey WC. Hyperlipidemia and obesity after orthotopic liver transplantation. Transplant Proc 1991; 23: 14801483.
  • 24
    Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 1998; 4: 285296.
  • 25
    Gisbert C, Prieto M, Berenguer M, Breto M, Carrasco D, de Juan M, et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg 1997; 3: 416422.
    Direct Link:
  • 26
    Dehghani SM, Taghavi SA, Eshraghian A, Gholami S, Imanieh MH, Bordbar MR, et al. Hyperlipidemia in Iranian liver transplant recipients: prevalence and risk factors. J Gastroenterol 2007; 42: 769774.
  • 27
    Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 1997; 3: 177178.
    Direct Link:
  • 28
    Carson K, Washington MK, Treem WR, Clavien PA, Hunt CM. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transpl Surg 1997; 3: 174176.
    Direct Link:
  • 29
    Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996; 62: 18021805.
  • 30
    Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001; 7: 608614.
  • 31
    Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363373.
  • 32
    Poordad F, Gish R, Wakil A, Garcia-Kennedy R, Martin P, Yao FY. De novo non-alcoholic fatty liver disease following orthotopic liver transplantation. Am J Transplant 2003; 3: 14131417.
  • 33
    Lim LG, Cheng CL, Wee A, Lim SG, Lee YM, Sutedja DS, et al. Prevalence and clinical associations of posttransplant fatty liver disease. Liver Int 2007; 27: 7680.
  • 34
    Seo S, Maganti K, Khehra M, Ramsamooj R, Tsodikov A, Bowlus C, et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 2007; 13: 844847.
  • 35
    Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 616627.
  • 36
    Perseghin G, Mazzaferro V, Benedini S, Pulvirenti A, Coppa J, Regalia E, et al. Resting energy expenditure in diabetic and nondiabetic patients with liver cirrhosis: relation with insulin sensitivity and effect of liver transplantation and immunosuppressive therapy. Am J Clin Nutr 2002; 76: 541548.
  • 37
    Tietge UJ, Selberg O, Kreter A, Bahr MJ, Pirlich M, Burchert W, et al. Alterations in glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation. Liver Transpl 2004; 10: 10301040.
  • 38
    Merli M, Leonetti F, Riggio O, Valeriano V, Ribaudo MC, Strati F, et al. Glucose intolerance and insulin resistance in cirrhosis are normalized after liver transplantation. Hepatology 1999; 30: 649654.
  • 39
    Alessiani M, Cillo U, Fung JJ, Irish W, Abu-Elmagd K, Jain A, et al. Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc 1993; 25: 628634.
  • 40
    Trail KC, McCashland TM, Larsen JL, Heffron TG, Stratta RJ, Langnas AN, et al. Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation. Liver Transpl Surg 1996; 2: 276283.
  • 41
    Davidson JA, Wilkinson A, for the International Expert Panel on New-Onset Diabetes After Transplantation. New-onset diabetes after transplantation 2003 international consensus guidelines: an endocrinologist's view. Diabetes Care 2004; 27: 805812.
  • 42
    Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Porayko MK, et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997; 3: 19.
    Direct Link:
  • 43
    Neal DA, Gimson AE, Gibbs P, Alexander GJ. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl 2001; 7: 533539.
  • 44
    Manzarbeitia C, Reich DJ, Rothstein KD, Braitman LE, Levin S, Munoz SJ. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. Liver Transpl 2001; 7: 9399.
  • 45
    Luke RG. Mechanism of cyclosporine-induced hypertension. Am J Hypertens 1991; 4: 468471.
  • 46
    Mor E, Facklam D, Hasse J, Sheiner P, Emre S, Schwartz M, et al. Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. Transplant Proc 1995; 27: 1126.
  • 47
    Abouljoud MS, Levy MF, Klintmalm GB, for the US Multicenter Study Group. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter trial. Transplant Proc 1995; 27: 11211123.
  • 48
    Meltzer AA, Everhart JE. Self-reported substantial 1-year weight change among men and women in the United States. Obes Res 1995; 3(suppl 2): 123s134s.
  • 49
    Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 11831192.
  • 50
    Guckelberger O, Mutzke F, Glanemann M, Neumann UP, Jonas S, Neuhaus R, et al. Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl 2006; 12: 394401.
  • 51
    Wahlstrom HE, Cooper J, Gores G, Rosen C, Wiesner R, Krom RA. Survival after liver transplantation in diabetics. Transplant Proc 1991; 23: 15651566.
  • 52
    Levy MF, Husberg BS, Goldstein RM, Backman L, McMillan RW, Gibbs JF, et al. Diabetes mellitus and liver transplantation. Hepatology 1992; 16: 50A.
  • 53
    Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis 2007; 11: 105117, ix.
  • 54
    Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899905.
  • 55
    Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 2000; 23: 16191629.
  • 56
    Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 16731679.